Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Theorem Clinical Research, Charles River Form Strategic Alliance

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
New alliance provides nonclinical testing programs.

Theorem Clinical Research has announced the formation of a strategic alliance with Charles River Laboratories that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration.

The new alliance provides nonclinical testing programs in the areas of bioanalysis, immunogenicity and immunology to support clinical trials.

“Charles River develops and validates assays in support of nonclinical programs, and many of these assays can be validated for human matrix and used for analyzing clinical samples,” said Dr. Marc Hoffman, Theorem senior vice president and general manager of biopharmaceutical development.

Charles River’s high-quality research models, preclinical testing capabilities and clinical support services are backed by a comprehensive bioanalysis portfolio for non-GLP and GLP programs.

Laboratories are equipped with the latest instrumentation to measure drug and metabolite concentrations in biological matrices and to provide full support for capillary micro sampling and dried blood spot analysis.

The variety of advanced equipment ensures the capacity to meet critical deadlines.

“We are pleased to partner with a world-class clinical trials organization like Theorem Clinical Research. Sponsors will benefit from the experience of both organizations. The alliance will offer a seamless transition from preclinical testing into the clinical arena,” said Alan Bartlett, executive director of laboratory services, Charles River Laboratories.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Theorem Clinical Research Expands Leadership and Prepares for Growth
Addition of Kathryn Bohannon as vice president of biopharmaceutical development and Angela Weston as vice president business development.
Thursday, November 13, 2014
Ximedica Joins Theorem Clinical Research Strategic Alliance Group
Will work to design medical solutions that meet a range of safety requirements.
Thursday, September 12, 2013
Theorem Adds RadMD to its Roster of Strategic Alliances
Expands imaging capabilities.
Friday, August 16, 2013
Theorem Clinical Research Distributes Clinical Trial Advice
Company releases booklets to provide ICH GCP guidance for in vitro and investigational product trials.
Thursday, February 28, 2013
Theorem and Gallus Announce an Exclusive Partnership
Partnership to help companies accelerate their research, development and manufacturing of biopharmaceuticals.
Monday, August 13, 2012
Theorem Clinical Research Appoints Vice President of Global Regulatory Affairs
The CRO has announced the appointment of food and drug law expert Brian Bollwage, J.D., as Vice President of Global Regulatory Affairs.
Wednesday, January 18, 2012
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!